The effect of ibrutinib on neutrophil and γδ T cell functions.

ELIAS E; PODAZA E.; KEITELMAN I; FERNÁNDEZ GRECCO H; CORDINI, GREGORIO; TREVANI A; BEZARES RF; - GAMBERALE R; GIORDANO M; RISNIK D; COLADO A; VERGARA RUBIO M; BORGE M; JANCIC C

LEUKEMIA AND LYMPHOMA

TAYLOR & FRANCIS LTD

Lugar: Londres; Año: 2020 p. 1 - 10

1042-8194

ABSTRACTIbrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers,including CLL. Considering that innate and adaptative immune defects are a dominant featureof CLL patients, we evaluated whether in vitro ibrutinib affects the survival and function of neutrophilsand cd T cells, key players of the early immune response against microbes. Neutrophilsand cd T cells were obtained from peripheral blood of healthy donors and CLL patients. Wefound that ibrutinib reduces the production of reactive oxygen species (ROS) and bacteria killingcapacity, and slightly impairs neutrophil extracellular traps (NETs) production without affectingbacteria-uptake and CD62L-downregulation induced by fMLP or aggregated IgG. In addition,ibrutinib reduces cd T cell activation and CD107a degranulation induced by phosphoantigens oranti-CD3. These findings are in agreement with previous data suggesting that ibrutinib interfereswith the protective immune response to pathogens, particularly Mycobacteria and Aspergillus